
## Small and Intermediate Calcium-Activated Potassium Channel Openers improve Rat Endothelial and Erectile Function


S Comerma-Steffensen<sup>1,2\*</sup>, I Carvacho<sup>1,3,4</sup>, E R Hedegaard<sup>1</sup>, and U Simonsen<sup>1</sup>

Supplementary figures


## Figure S1A



## Figure S1B



## Figure S1C



**Suppl. Figure S1 A)** Original membrane showing markers visualized by epi-luminescence, **B)** The same membrane exposed to cheminoluminescence to reveal the immunoblotting for  $K_{Ca}2.3$  channels in the heart and *corpus cavernosum* of the rat and **C)** Original cheminoluminescense of

membrane of pan-actin antibody in heart and *corpus cavernosum* of the rat. Heart n=5 and *corpus cavernosum* n=14.

Figure S2A






Figure S2B





**Suppl. Figure S2. A)** Original membrane showing markers visualized by epi-luminescence, **B)** The same membrane exposed to chemiluminescence to reveal the immunoblotting for  $K_{Ca}1.1$  samples in

heart and *corpus cavernosum* (CC) of the rat, **B**) Original chemiluminescence blotting of  $K_{Ca}1.1$  antibody in heart and *corpus cavernosum* (CC) of the rat. Heart n=6 and *corpus cavernosum* n=11. C) Original chemiluminescence picture showing  $K_{Ca}1.1$  alpha in *corpus cavernosum* (CC) of the rat. Mesenteric artery n=3, *corpus cavernosum* n=3 and Liver n=2. Left side membrane of is shown minus peptide and right side incubated with peptide used to raise the antibody for  $K_{Ca}1.1$ .

Figure S3A







Figure S3B




**Suppl. Figure S3. A)** Original membrane epi-illumination of  $K_{Ca}3.1$  antibody in heart and *corpus cavernosum* (CC) of the rat **B)** Original chemiluminescence (blotting) of  $K_{Ca}3.1$  antibody in heart and *corpus cavernosum* (CC) of the rat.  $K_{Ca}3.1$  knockout mouse (IKKO) heart n=1, Rat heart n= 3 and *corpus cavernosum* n=12.




**Suppl. Figure S4.** Whole-cell voltage clamp recordings of currents evoked from voltage steps in primary cultures of endothelial cells from rat *corpus cavernosum*. (A) Whole-cell voltage clamp recordings of currents evoked from voltage steps (-140 to +140 mV) in control cells (*filled circles*) or in presence of 0,5 μM apamin (*filled diamonds*). (B) Whole-cell voltage clamp recordings of currents evoked from voltage steps (-140 to +140 mV) in control cells (*filled circles*) or in presence of 1 μM TRAM-34 (*open circles*). Cells were obtained from 3 different rats.



**Suppl. Figure S5.** (A) Whole cell patch clamp recording in human umbilical vein endothelial cell showing the effect of NS309 (0.1 $\mu$ M) in the presence (Ca<sup>2+</sup>, 1.6 mM) and the absence of intracellular (Ca<sup>2+</sup>-free) calcium. (B) Relative NS309 (0.1  $\mu$ M) -induced increase in current in HUVECs in the presence and the absence (Ca-free) of calcium and the presence of calcium and different K channel blockers, apamin, TRAM-34 (1  $\mu$ M), iberiotoxin (IbTx, 0.1  $\mu$ M), and glybenclamide (0.1  $\mu$ M). Modified from Stankevicius et al., 2011. Data are expressed as means  $\pm$  S.E.M. \*P $\leq$ 0.05, significantly different from control. Human umbilical venous endothelial cells – HUVEC.




Suppl. Figure S6. Relaxations by induced by NS4591 in rat *corpus cavernosum*. (A) Effect of vehicle PEG 100% and of NS4591 in rat *corpus cavernosum* strips contracted with noradrenaline. (B) Relaxations induced by NS4591 in preparations with (n=5) and without endothelium (n=5). \*P≤0.05, curves were significantly different, two-way ANOVA followed by a Bonferroni post-test.



**Suppl. Figure S7.** Effect of high extracellular potassium on acetylcholine and NS309 relaxation of rat *corpus cavernosum*. Concentration-response curves for **A**) acetylcholine (ACh) in the absence (n=5) and the presence of high extracellular potassium (60 mM KPSS, n=5), **B**) NS309 in the absence (n=6) and the presence of a blocker of Kv7 channels. Linopirdine (10  $\mu$ M, n=6). Data are expressed as means  $\pm$  S.E.M. \*P $\leq$ 0.05, curves were significantly different, two-way ANOVA followed by a Bonferroni post-test.

A



Suppl. Figure S8. Changes of and mean arterial pressure during and 1 min after infusion of NS309 and NS4591. (A) Changes in erectile function measured as intracavernosal pressure over mean arterial pressure ( $\Delta$ ICP/MAP\*100) induced by (A) the vehicle DMSO (n=7), NS309 (1 mg/Kg, n=5), the vehicle PEG (n=7), and NS4591 (1 mg/kg, n=6), and (B) changes in mean arterial pressure ( $\Delta$ MAP, mmHg) induced by DMSO, NS309 (1 mg/Kg), PEG and NS4591 (1 mg/kg). Data are expressed as means  $\pm$  S.E.M. \*P $\leq$ 0.05, significantly different compared to vehicle using Student's t-test.